Move your Lyme disease testing ahead in 2022 with ZEUS Scientific's Borrelia MTTT algorithm
Get ready for 2022 Lyme disease season
with ZEUS Borrelia MTTT™
Do you have questions? ZEUS has answers.
Let us provide you with a thorough understanding of transitioning from the Standard Two-Tiered Testing (STTT) algorithm to the first FDA-cleared Modified Two-Tiered Testing (MTTT) algorithms.
Join our monthly Lyme disease testing sessions to have your questions answered. Sign up today for your personal expert consultation. Next session is March 16, 2022, from 9am to 4pm EDT.
Change is easier than you think!
Are you still following STTT and using immunoblots or sending out to have them run in another laboratory? If you are ready to make the change to a more accurate Lyme disease testing algorithm, let us help you convert to ZEUS Borrelia MTTT!
With over 30 years of experience in developing and delivering high quality Lyme disease tests, we have the knowledge and experience you need to make a seamless transition to the first FDA-cleared Modified Two-Tiered (MTTT) testing paradigm available: the ZEUS Borrelia MTTT algorithms.
Let the experts in Lyme disease testing help! Make 2022 the year you join other laboratories who have made the switch to the ZEUS Borrelia MTTT algorithm.
|RSVP for March 16, 2022|
Why make the switch?
ZEUS Borrelia MTTT uses two rounds of ZEUS ELISA tests, enabling simple and flexible first-tier and second-tier testing in-house. This allows you to consolidate your Lyme disease testing processes and streamline your workflow.
The ZEUS Borrelia MTTT reduces turnaround time, allowing patients to access much-needed treatment earlier. Without early treatment, Lyme disease can have a devastating impact on patients.
Our updated algorithm detected up to 30% more clinically confirmed positive patients in acute early Lyme disease, the critical time to correctly identify and treat! Reducing the number of missed clinically positive patient samples especially in early Lyme disease stages 1 and 2 can make a real difference in a person’s life.
But that's not all.
Partnering with ZEUS Scientific means partnering with over 40 years of experience in developing, manufacturing and delivering high-quality in vitro diagnostic (IVD) products. Particularly, ZEUS has been a pioneer in Lyme disease diagnostics. From the first FDA-cleared Lyme serology test in 1987, to the first FDA-cleared Borrelia MTTT algorithm method of testing for Lyme disease in 2019, it is no wonder that ZEUS has been recently featured on Lifetime Network's Access Health program.
Trust the experts in Lyme disease testing.
Test with Confidence. Test with ZEUS.
Simplify your testing. Contact ZEUS today!
Visit zeuslyme.com to learn more.
The ZEUS Scientific TeamBack Share